TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating on November 13.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ritu Baral’s rating is based on several positive developments surrounding Neurogene’s ‘401 program. The recent Phase 1/2 data for ‘401 demonstrated consistent and durable improvements across multiple domains, suggesting that ‘401 could be a leading treatment option. A significant majority of patients met the responder criteria for the EMBOLDEN trial, surpassing the expected success rate, which is a promising indicator for the upcoming Phase 3 results. Additionally, the ‘401 treatment was found to be safe and well-tolerated, with no severe adverse events reported.
Financially, Neurogene appears to be in a strong position, with a cash runway expected to last until the first quarter of 2028. This financial stability supports continued development and potential commercialization of ‘401. The combination of promising clinical data and a solid financial foundation underpins Ritu Baral’s Buy rating for Neurogene’s stock.
According to TipRanks, Baral is a top 100 analyst with an average return of 32.3% and a 57.03% success rate. Baral covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Palvella Therapeutics, and Avidity Biosciences.